Celebrating Chinese Doctor’s Day!
On August 19th, we honor the incredible dedication and compassion of doctors who work tirelessly to safeguard our health. Let's take a moment to appreciate their unwavering commitment to preserving…
Cutting-edge Bi-monthly: July Literature Digest (Part 1)
Introduction: In this era of information explosion, how can one quickly access the latest developments in the field? Here, we select the latest literature in the field every month, focusing…
Dr. Zefei Jiang: Highlights, Innovations, and Reflections | 2024 Breast Cancer Summer Forum · Northern Salon
Editor's Note: On July 27-28, 2024, the "2024 Breast Cancer Summer Forum · Northern Salon" was grandly held at Beijing Shougang Park. The conference upheld the philosophy of "learning and…
Dr. Nicolaus Kroger: New Perspectives on Myelofibrosis Treatment – Focusing on Post-Transplant Management and Minimal Residual Disease Monitoring
In the field of myelofibrosis treatment, allogeneic hematopoietic stem cell transplantation (allo-HSCT) serves as a curative approach, and the optimization of related strategies is particularly crucial. Recently, at the 12th…
Phase 3 EMBER-3 Trial: Imlunestrant in Advanced Breast Cancer
A study published in NEJM on December 11, 2024, led by Komal L. Jhaveri and colleagues, evaluated Imlunestrant, a next-generation oral selective estrogen receptor (ER) degrader, in ER-positive, HER2-negative advanced…
Three First-Line Strategies for EGFR-Mutant NSCLC: How to Choose the Right One?
Clinicians and researchers continue to seek targeted treatment strategies for EGFR-mutant non-small cell lung cancer (NSCLC), with an increasing number of clinical trials evaluating combination therapies. Two recent high-profile studies, the FLAURA-2 and MARIPOSA trials, have led to the FDA approval of new first-line treatment options for EGFR-mutant NSCLC in 2024.
Honoring Dr. Abdullah Tarik Aslan and His Research on Antibiotic-Associated Nephrotoxicity
Dr. Abdullah Tarik Aslan, alongside his colleagues, has led an important multinational, multicenter cohort study investigating the risk of acute kidney injury (AKI) in patients receiving piperacillin-tazobactam (TZP) with either vancomycin (VAN) or teicoplanin (TEI).
Unlocking the Potential of Antibody-Drug Conjugates in Pancreaticobiliary Cancers: Mechanisms and Key Selection Criteria
Antibody-drug conjugates (ADCs) have emerged as a promising treatment modality for pancreaticobiliary cancers, offering targeted delivery of cytotoxic agents while minimizing systemic toxicity. Dr. Lei Zheng’s presentation at the ASCO…
ASCO GI Highlights! A Breakthrough for Cadonilimab in Gastrointestinal Cancers
From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) was held in San Francisco, USA. At this prestigious event, Cadonilimab, the world's first bispecific antibody developed in China, achieved multiple breakthroughs in the treatment of gastrointestinal cancers.Several research teams, including Professors Jing Huang and Wang Qu from the Cancer Hospital Chinese Academy of Medical Sciences, Professor Rongbo Lin from Fujian Cancer Hospital, and Professor Wan He from Shenzhen People's Hospital, presented the latest research findings on Cadonilimab in the treatment of advanced esophageal squamous cell carcinoma (ESCC), mismatch repair-proficient/microsatellite-stable (pMMR/MSS) metastatic colorectal cancer (mCRC), and locally advanced rectal cancer (LARC). These studies demonstrated the potential of Cadonilimab-based combination therapies to enhance anti-tumor efficacy, prolong survival, and improve safety, laying the foundation for a new era of bispecific antibody therapy in gastrointestinal cancers.
ASCO GI 2025 | CD47 Blockade Combination Therapy Shows Anti-Tumor Potential in Previously Treated HER2-Positive Gastric Cancer
The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. During the conference, numerous high-impact research findings were presented, including the ASPEN-06 study (Abstract #332), a global Phase II/III randomized trial evaluating the efficacy of evorpact (Evo) in combination with trastuzumab, ramucirumab, and paclitaxel (TRP) in patients with HER2-positive gastric and esophageal cancer who had previously received anti-HER2 therapy but experienced disease progression. At the conference, a reporter from Oncology Frontier had the opportunity to conduct an exclusive interview with Dr. Kohei Shitara from the National Cancer Center Hospital in Japan regarding this study. The following is a summary of the discussion.